Syncromune, Inc.
PrivateLast Round
Series B
May 11, 2026
Est. Valuation
$242M
Total Funding Raised
$145M
Momentum Score
25 /100
Company Overview
Syncromune, Inc. is a clinical-stage biopharmaceutical company developing SYNC-T, an in situ immunotherapy platform designed to treat metastatic solid tumor cancers by combining partial oncolysis with a multi-target biologic drug infusion.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Medical Devices
Business Model
B2B
Customer Profile
Hardware + Subscription, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Syncromune, Inc. Comps
Public and private peers based on sector, stage, and business model.
Syncromune, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 11, 2026 | ||||
| Series A | Dec 20, 2024 | ||||
| Convertible Debt | Nov 15, 2022 |
Key People
Founding team and executive leadership
Syncromune, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Wasatch Equity Partners | Series A, Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 11, 2026
$145M round completed.
- Jan 6, 2026
Dr. Stephen P. Dale appointed as new Chief Medical Officer.
Syncromune, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Syncromune, Inc.'s valuation, stock price, and market status.
